Navigation Links
Data on ElectroCore's Vagal Nerve Stimulation Therapy GammaCore Selected for an Oral Presentation at the 65th American Academy of Neurology Annual Meeting
Date:3/13/2013

MORRIS PLAINS, N.J., March 13, 2013 /PRNewswire/ -- ElectroCore®, a company dedicated to developing effective, non-invasive Vagal Nerve Stimulation (nVNS) therapies for serious medical conditions including primary headaches, announced today that data demonstrating the efficacy of its GammaCore® therapy as an acute treatment for migraine was accepted for an oral presentation at the American Academy of Neurology Annual Meeting March 16-23 in San Diego.

The open-label pilot study "Non-Invasive Neurostimulation of the Vagus Nerve with the GammaCore Device for the Relief of Symptoms Associated with Migraine" was conducted by Peter Goadsby , M.D., director of the University of California San Francisco Headache Center; Roger Cady , M.D., founder of the Headache Care Center; Brian Grosberg , M.D., director of the Montefiore Headache Center and Alexander Mauskop , founder and director of the New York Headache Center. The data will be presented on Wednesday, March 20, at 4:39 p.m. PDT in the Moderated Platform Session S40: Headache: Clinical.

"The study's results suggest GammaCore's non-invasive vagal nerve stimulation to potentially be an effective and well-tolerated acute treatment for migraine," said J.P. Errico , CEO of ElectroCore. "One-third of all patients who were treated while experiencing mild, moderate or severe pain were pain free at two hours."

In the study, 27 enrolled participants treated an acute migraine with a portable nVNS device (GammaCore). Treatment consisted of two, 90-second doses, at 15-minute intervals delivered to the right cervical branch of the vagus nerve. Two-thirds of patients treated at mild pain were pain free at two hours. Treatment related adverse effects were limited.

"We are currently enrolling our FDA-approved chronic migraine prevention study at several sites across the U.S., with an initial readout expected later this year," said Errico.  "We believe the study will further demonstrate the efficacy of GammaCore as an important new treatment option for the many Americans who suffer from migraine."

For more information about ElectroCore's AAN presentation, visit  http://www.abstracts2view.com/aan/view.php?nu=AAN13L_S40.004.

About GammaCore®
GammaCore is a non-invasive, vagus nerve stimulator that produces a mild electrical signal which is transmitted to the vagus nerve through the skin. It's indicated for the acute and/or prophylactic treatment of migraine, cluster headache, and medication overuse headache (MOH) in adults. GammaCore is currently available in the European Union, South Africa, India, New Zealand, Australia, Colombia and Malaysia for the acute and/or prophylactic treatment of migraine, cluster headache, and MOH in adults. GammaCore is available in Canada for cluster headache only.

About ElectroCore®
ElectroCore is a healthcare company focused on non-invasive neuromodulation therapies for the treatment of diseases and disorders. The company has developed non-invasive Vagal Nerve Simulation (nVNS) therapies intended to treat and/or prevent symptoms of a number of highly prevalent and disabling conditions. ElectroCore currently has three commercial products on the market: GammaCore®, AlphaCore®, and GammaCore VET™. The company is headquartered in Morris Plains, NJ, with international offices in Stockholm, Sweden, Hamilton, Bermuda, and Sydney, Australia.

For more information, visit: http://www.electrocoremedical.com/.


'/>"/>
SOURCE ElectroCore Medical
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. NeuroSigma Announces Receipt of Notice of Allowance of U.S. Patent Application Related to External Trigeminal Nerve Stimulation (eTNS) for the Treatment of Neuropsychiatric Disorders
2. Study Demonstrates Percutaneous Tibial Nerve Stimulation Offers More Cost-Effective OAB Treatment Than Sacral Nerve Stimulation
3. New Candidate Drug Stops Cancer Cells, Regenerates Nerve Cells
4. Interim Results Reported for Phase I Open-Label Clinical Trial for the Treatment of PTSD and MDD Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
5. Percutaneous Tibial Nerve Stimulation Included in the American Urological Associations Overactive Bladder Clinical Treatment Guidelines
6. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
7. Lower Extremity Functional Electrical Stimulation Cycling Promotes Physical & Neurological Recovery in Chronic Spinal Cord Injury
8. Deep Brain Stimulation Clinic Expedites Patient Treatment at Muhammad Ali Parkinson Center
9. Analysis of the U.S. Neurostimulation Market
10. Global Neurostimulation Industry
11. Texas Childrens Hospital is first in North America to own Leica Microsystems Gated Stimulation Emission Depletion microscope
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Consumers have ... and regulators/payers have placed more emphasis on patient ... patient support programs in the pharmaceutical industry have ... medications. Consequently, pharmaceutical companies are focusing on becoming ... are providing products and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016 ... the "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural ... Structural electronics involves electronic and/or ... protective structures, replacing dumb structures such as vehicle ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... ... , ... People across the U.S. are sharpening their pencils and honing their ... in which patients and their families pay tribute to a genetic counselor by nominating ... of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
(Date:6/24/2016)... ... , ... Venture Construction Group (VCG) sponsors Luke’s Wings ... the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event ... that have been wounded in battle and their families. Venture Construction Group is a ...
Breaking Medicine News(10 mins):